Cover Image
市場調查報告書

EpiCast Report:黑色素瘤的流行病學的預測 (∼2023年)

EpiCast Report: Melanoma - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 331729
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:黑色素瘤的流行病學的預測 (∼2023年) EpiCast Report: Melanoma - Epidemiology Forecast to 2026
出版日期: 2017年10月03日 內容資訊: 英文 30 Pages
簡介

全球主要8個國家(美國、法國、德國、義大利、西班牙、英國、日本、澳洲) 的黑色素瘤的診斷病例數,預計從2013年到2023年以3.39%的年成長率推移,從2013年的155,057件至2023年達到207,606件。還有主要8個國家5年的累積患病人數,預計從2013年的639,165件到2023年擴大到860,889件。

本報告提供全球主要8個國家黑色素瘤的診斷病例數及死亡人數的變化的相關調查、疾病的背景、風險要素和並存症、各年齡、性別、重症度、原因病原的診斷病例數及死亡人數的預測等相關彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險要素與並存症
  • 全球趨勢
    • 美國
    • 歐盟5國
    • 日本、澳洲
  • 預測手法
    • 使用來源
    • 未使用來源
    • 預測的前提條件、手法
  • 黑色素瘤的流行病學預測
    • 診斷病例數
    • 診斷病例數:各年齡
    • 診斷病例數:性別
    • 標準診斷案例的比例:各年齡
    • 診斷的分期
    • 5年的患病人數
    • 5年的患病人數:遺傳基因異常
  • 檢驗
    • 流行病學的預測考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考資料
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER161-17

Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin (WHO, 2014). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes-namely areas of skin, meninges, mucous membranes, esophagus, and eyes-can develop melanoma (Komarnicky-Kocher and Alite, 2013).

In the 7MM, our epidemiologists forecast the diagnosed incident cases of melanoma to increase to over 200,000 cases by 2026, at an Annual Growth Rate (AGR) of almost 2.5%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagnosed prevalent cases of melanoma in the 7MM are also expected to increase from almost 0.75 million cases in 2016 to over 900,000 cases in 2026 at an AGR of over 2.5%.

Australia has the highest age-standardized incidence rate of melanoma in the 7MM by a significant margin. In 2016, incidence of melanoma in Australian men was over 60 cases per 100,000, and over 41.59 cases per 100,000 in Australian women. The second highest age-standardized incidence of melanoma in men was in the US, at about 30 cases per 100,000 of its population. The UK had the second highest incidence rate in women, at about 20 cases per 100,000. Over the forecast period, the age-standardized incidence rates of melanoma will remain largely unchanged, with the greatest growth seen in Germany from 2006-2011.

The report "EpiCast Report: Melanoma - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends for melanoma of the skin in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases of melanoma segmented by age (beginning at 18 years and ending at 80 years and older), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] Stages I, II, III, and IV).

Scope

  • The Melanoma EpiCast Report provides an overview of the risk factors and global trends of melanoma in the 7MM (US, France, Germany, Italy, Spain, UK, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of melanoma segmented by age (beginning at 18 years and ending at 80 years and older), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] Stages I, II, III, and IV).
  • The melanoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Melanoma EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global melanoma market.
  • Quantify patient populations in the global melanoma market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for melanoma therapeutics in each of the markets covered.
  • Compare patient population potentials by age, sex, stage at diagnosis, and survival.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Melanoma: Executive Summary 4

  • 2.1 Related Reports 7
  • 2.2 Upcoming Reports 7

3 Epidemiology 8

  • 3.1 Disease Background 8
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 9
  • 3.4 Forecast Methodology 11
    • 3.4.1 Sources 12
    • 3.4.2 Forecast Assumptions and Methods 14
  • 3.5 Epidemiological Forecast for Melanoma (2016-2026) 18
    • 3.5.1 Diagnosed Incident Cases of Melanoma 18
    • 3.5.2 Age-Specific Diagnosed Incident Cases of Melanoma 20
    • 3.5.3 Sex-Specific Diagnosed Incident Cases of Melanoma 21
    • 3.5.4 Five-Year Diagnosed Prevalent Cases of Melanoma 21
    • 3.5.5 Diagnosed Incident Cases of Melanoma by Stage at Diagnosis 23
  • 3.6 Discussion 23
    • 3.6.1 Epidemiological Forecast Insight 23
    • 3.6.2 Limitations of Analysis 24
    • 3.6.3 Strengths of Analysis 24

4 Appendix 25

  • 4.1 Bibliography 25
  • 4.2 About the Authors 28
    • 4.2.1 Epidemiologist 28
    • 4.2.2 Reviewers 28
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 29
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 29
  • 4.3 About GlobalData 30
  • 4.4 Contact Us 30
  • 4.5 Disclaimer 30

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors for Melanoma of the Skin 9
  • Table 2: 7MM, Diagnosed Incident Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016-2026 19
  • Table 3: 7MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016-2026 22

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of Melanoma, Men and Women, Ages ≥18 Years, 2016 and 2026 5
  • Figure 2: 7MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Men and Women, Ages ≥18 Years, 2016 and 2026 6
  • Figure 3: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Men, Ages ≥18 Years, 2006-2026 10
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Women, Ages ≥18 Years, 2006-2026 11
  • Figure 5: 7MM, Sources Used and Not Used to Forecast Diagnosed Incident Cases of Melanoma, 2016 12
  • Figure 6: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of Melanoma, 2016 13
  • Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, 2016 14
  • Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of Melanoma, Men and Women, 2016 20
  • Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of Melanoma, Ages ≥18 Years, 2016 21
  • Figure 10: 7MM, Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, Men and Women, Ages ≥18 Years, 2016 23
Back to Top